- Home
- ELVN vs SPHR Comparison
ELVN vs SPHR Comparison
Compare ELVN & SPHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SPHR
- Stock Information
- Founded
- ELVN 2016
- SPHR 2020
- Country
- ELVN United States
- SPHR United States
- Employees
- ELVN N/A
- SPHR N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SPHR Services-Misc. Amusement & Recreation
- Sector
- ELVN Health Care
- SPHR Consumer Discretionary
- Exchange
- ELVN Nasdaq
- SPHR Nasdaq
- Market Cap
- ELVN 1.1B
- SPHR 970.6M
- IPO Year
- ELVN 2020
- SPHR N/A
- Fundamental
- Price
- ELVN $16.53
- SPHR $25.38
- Analyst Decision
- ELVN Strong Buy
- SPHR Buy
- Analyst Count
- ELVN 4
- SPHR 9
- Target Price
- ELVN $39.25
- SPHR $47.00
- AVG Volume (30 Days)
- ELVN 359.8K
- SPHR 958.6K
- Earning Date
- ELVN 05-13-2025
- SPHR 05-09-2025
- Dividend Yield
- ELVN N/A
- SPHR N/A
- EPS Growth
- ELVN N/A
- SPHR N/A
- EPS
- ELVN N/A
- SPHR N/A
- Revenue
- ELVN N/A
- SPHR $1,072,406,000.00
- Revenue This Year
- ELVN N/A
- SPHR $8.54
- Revenue Next Year
- ELVN N/A
- SPHR $7.22
- P/E Ratio
- ELVN N/A
- SPHR N/A
- Revenue Growth
- ELVN N/A
- SPHR 48.26
- 52 Week Low
- ELVN $13.30
- SPHR $24.77
- 52 Week High
- ELVN $30.03
- SPHR $50.88
- Technical
- Relative Strength Index (RSI)
- ELVN 40.34
- SPHR 32.88
- Support Level
- ELVN $15.49
- SPHR $24.60
- Resistance Level
- ELVN $18.14
- SPHR $31.05
- Average True Range (ATR)
- ELVN 1.93
- SPHR 2.43
- MACD
- ELVN -0.17
- SPHR -0.14
- Stochastic Oscillator
- ELVN 41.09
- SPHR 8.43
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.